Iversen, Philip W.
Eli Lilly (United States)
4 papers on CoChat
Most cited papers
- Verified
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs
Cancer-related Molecular PathwaysAdvanced Breast Cancer Therapies
Cited by 577
- Verified
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports
Cancer Immunotherapy and BiomarkersAdvanced Breast Cancer Therapies
Cited by 469
- Verified
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., et al. (2018) · Journal for ImmunoTherapy of Cancer
TGF-β signaling in diseasesCancer Immunotherapy and Biomarkers
Cited by 356
- Verified
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first‐in‐class transforming growth factor‐β receptor type I inhibitor
Yingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., Clawson, D. K., Britt, K. S., Anderson, B. D., Beight, D. W., et al. (2018) · Oncotarget
TGF-β signaling in diseasesMechanisms of cancer metastasis
Cited by 187
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free